{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T07:33:58Z","timestamp":1769758438841,"version":"3.49.0"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,3,26]],"date-time":"2022-03-26T00:00:00Z","timestamp":1648252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,26]],"date-time":"2022-03-26T00:00:00Z","timestamp":1648252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100010722","name":"Harbin Medical University","doi-asserted-by":"publisher","award":["YKCX2018-15"],"award-info":[{"award-number":["YKCX2018-15"]}],"id":[{"id":"10.13039\/100010722","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003472","name":"Harbin Institute of Technology","doi-asserted-by":"publisher","award":["No.JH20180176"],"award-info":[{"award-number":["No.JH20180176"]}],"id":[{"id":"10.13039\/501100003472","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s00277-022-04823-w","type":"journal-article","created":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T21:06:32Z","timestamp":1648501592000},"page":"1865-1867","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Central nervous system relapse of acute promyelocytic leukemia treated by oral Venetoclax with Azacitidine achieved complete remission"],"prefix":"10.1007","volume":"101","author":[{"given":"Yanling","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haibin","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dandan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanming","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,26]]},"reference":[{"issue":"6","key":"4823_CR1","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","volume":"11","author":"VA Pullarkat","year":"2021","unstructured":"Pullarkat VA, Lacayo NJ, Jabbour E, Rubnitz JE, Bajel A, Laetsch TW, Leonard J, Colace SI, Khaw SL, Fleming SA, Mattison RJ, Norris R, Opferman JT, Roberts KG, Zhao Y, Qu C, Badawi M, Schmidt M, Tong B, Pesko JC, Sun Y, Ross JA, Vishwamitra D, Rosenwinkel L, Kim SY, Jacobson A, Mullighan CG, Alexander TB, Stock W (2021) Venetoclax and Navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov 11(6):1440\u20131453","journal-title":"Cancer Discov"},{"issue":"5","key":"4823_CR2","doi-asserted-by":"publisher","first-page":"e222","DOI":"10.3324\/haematol.2018.213157","volume":"104","author":"G Reda","year":"2019","unstructured":"Reda G, Cassin R, Dovrtelova G, Matteo C, Giannotta J, D\u2019Incalci M et al (2019) Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement. Haematologica 104(5):e222\u2013e223","journal-title":"Haematologica"},{"issue":"6","key":"4823_CR3","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","volume":"11","author":"VA Pullarkat","year":"2021","unstructured":"Pullarkat VA, Lacayo NJ, Jabbour E, Rubnitz JE, Bajel A, Laetsch TW et al (2021) Venetoclax and Navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov 11(6):1440\u20131453","journal-title":"Cancer Discov"},{"key":"4823_CR4","doi-asserted-by":"publisher","first-page":"693670","DOI":"10.3389\/fonc.2021.693670","volume":"11","author":"X Zhang","year":"2021","unstructured":"Zhang X, Chen J, Wang W, Li X, Tan Y, Zhang X et al (2021) Treatment of central nervous system relapse in acute promyelocytic leukemia by Venetoclax: a case report. Front Oncol 11:693670","journal-title":"Front Oncol"},{"issue":"4","key":"4823_CR5","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1002\/ccr3.4002","volume":"9","author":"M Dimou","year":"2021","unstructured":"Dimou M, Bitsani A, Roumelioti M, Dimitrakopoulou A, Iliakis T, Pardalis V et al (2021) Richter\u2019s transformation as leptomeningeal infiltration in a chronic lymphocytic leukemia patient receiving venetoclax. Could blood-brain barrier be a disease \u201csanctuary\u201d during venetoclax treatment? Clin Case Rep 9(4):2249\u20132253","journal-title":"Clin Case Rep"},{"issue":"8","key":"4823_CR6","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1007\/s00277-019-03719-6","volume":"98","author":"R Ram","year":"2019","unstructured":"Ram R, Amit O, Zuckerman T, Gurion R, Raanani P, Bar-On Y et al (2019) Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study. Ann Hematol 98(8):1927\u20131932","journal-title":"Ann Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04823-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-04823-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04823-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T13:07:15Z","timestamp":1657717635000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-04823-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,26]]},"references-count":6,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["4823"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-04823-w","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,26]]},"assertion":[{"value":"6 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declarations"}},{"value":"Informed consent was obtained from the patient for the treatment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}